Spontaneous pseudomembranous colitis
Pseudomembranous colitis is a well recognised complication of antibiotic treatment. In the absence of antibiotics it may occur after surgery and in patients with chronic debilitating illnesses. ' We report the case of a young man with pseudomembranous colitis in whom no predisposing factors could be identified. We have been unable to find similar cases in English-language publications.
Case report
A previouslyhealthy 22-year-old man presented with a four-week history of worsening abdominal pain and diarrhoea. On admission to hospital he had cramping lower abdominal pain with six watery, malodorous stools a day. The stools contained mucus and small amounts of blood. On examination he was afebrile, but had moderate generalised abdominal tenderness. Sigmoidoscopy showed oedematous, non-friable mucosa with adherent, discrete, grey-yellow plaques. Biopsy of the mucosa showed superficial inflammation and pseudomembrane. A barium enema showed mucosal plaques throughout the large bowel.
Stool cultures for salmonella, shigella, campylobacter, and yersinia were negative as were examinations for ova and parasites. Stools were cultured on CCFA agar (cycloserine, cefoxitin, fructose, and egg yolk) incubated anaerobically, and an ultraviolet fluorescent organism was isolated.2 The organism was identified by gas chromatography and API-20A carbohydrate utilisation as Clostridium difficile. Unfortunately clostridial toxins were not looked for.
Vancomycin 250 mg orally every 8 hours led to complete resolution of the patient's symptoms within 48 hours. After four days of treatment sigmoidoscopy showed complete resolution of the pseudomembrane, with only moderate mucosal oedema. Stool cultures three and six weeks after treatment were negative for C diBficile. Five months after treatment the patient remained asymptomatic.
Sixmonths before the onset of symptoms the patient had taken an eight-day course of amoxicillin for a penile cellulitis. Several months before this he had been on daily tetracycline for acne. Since the course of amoxicillin he had taken no antibiotics.
Comment
Pseudomembranous colitis is a toxin-induced diarrhoeal disorder usually associated with antibiotic use, surgery, or chronic illness. Profuse watery, non-bloody diarrhoea, abdominal pain, fever, and leucocytosis are common. Grey, white, or yellow plaques on the rectal mucosa are usually seen at sigmoidoscopy. The lesions consist of a fibrinopurulent exudate streaming from the lamina propria. Toxinproducing C difficile is usually recovered in cases of pseudomembranous colitis but is rarely found in patients with other bowel disorders.3 After stopping other antibiotics, recognised treatment consists of supportive therapy and oral vancomycin.
This case of pseudomembranous colitis was in a young man with no history of surgery, systemic illness, or recent antibiotic use. Major symptoms were abdominal pain and watery diarhoea with small amounts of blood. Before sigmoidoscopy pseudomembranous colitis had not been considered. Nevertheless, the diagnosis of pseudomembranous colitis was then established by the sigmoidoscopic appearance, rectal biopsy, and by barium enema. C difficile was cultured from the stool. The patient responded promptly to oral vancomycin.
We have reviewed published work and found no other cases of pseudomembranous colitis without predisposing factors. Malcolm4 reported an elderly lady with pseudomembranous colitis four years after a colectomy for Crohn's disease. There were no other predisposing factors. C difficile was searched for but not isolated in his patient.
Our patient took antibiotics six months before the onset of his symptoms, but it is difficult to implicate these as the cause of his illness. We cannot be certain that he did not take any antibiotics, but his history was consistent at all times to all physicians. We have no reason to believe otherwise. Myocarditis is a well-documented but rare complication of mumps. Although recovery is usually complete, death several months after the acute infection from heart failure due to the damaged myocardium has occasionally been described.' 2 We report a fatal case of mumps myocarditis which presented as a "cot death" in a previously healthy baby.
Case report An 8-month-old girl was found in her pram early one afternoon sweating profusely and with mottled blue patches on her face. She was taken to hospital by ambulance but was dead on arrival. She was being looked after by her grandmother at the time. There was no history of illness immediately before death or previously; she had been bottle fed and had been born after 39 weeks' gestation by spontaneous vertex delivery. After birth she had been initially floppy and irritable, but she was discharged from hospital when 1 week old and was well at follow-up examination six months later. At necropsy the heart was enlarged owing to gross dilatation of all the chambers, and there was a clear yellow pericardial effusion of about 5 ml. No congenital abnormalities of the heart or main vessels were found and, apart from congestion, the other organs appeared normal. Microscopy showed diffuse infiltration of the myocardium by lymphocytes and occasional polymorphonuclear leucocytes (figure) and a mild pericarditis. The parotid glands were not examined but the submandibular glands were examined as part of an investigation of cot deaths. They showed pronounced focal infiltration by lymphocytes and plasma cells, particularly around small ducts. The submucosa of the larynx, trachea, and nasopharynx was also infiltrated with these cells, and there were scattered interstitial aggregates of lymphoid cells in the skeletal muscle.
The cause of the acute myocarditis was established when mumps virus was isolated from the myocardium, and an impression smear of the myocardium tested by indirect immunofluorescence showed mumps virus antigen. On retesting, mumps virus was again isolated from the heart. No virus was isolated from a nasopharyngeal aspirate, the lungs, or faeces, and bacteriological and biochemical investigations showed no other abnormalities. 
The sudden death of this baby was due to acute myocarditis caused by mumps virus. The infiltration of the submandibular glands and the submucosa of the upper respiratory tract with lymphocytes is compatible with this diagnosis. Although the baby had two older siblings, aged 2 and 4 years, there was no recorded history of illness in these children during the preceding weeks; the source of infection cannot therefore be established.
Although transient electrocardiographic changes are quite common during mumps,3 clinical symptoms and signs of myocarditis are rare. Thus only one of 716 children admitted to hospital with mumps in Athens from 1950 to 1964 had a recognised cardiac lesion,4 and there was only one case of myocarditis reported in a retrospective study of 2482 cases of mumps treated in infectious disease units in England and Wales from 1958 to 1969.5 One of the three deaths in the latter survey may have been due to acute myocarditis, but confirmatory histological and virological studies were not reported. Other deaths ascribed to mumps myocarditis have occurred from heart failure several months after the acute infection.1 2 This appears to be the first report of mumps myocarditis causing sudden death in infancy.
We thank Dr S K R Clarke for her advice and the staff of the virology section ofthe Bristol Public Health Laboratory for their help in the virological investigations. 
Patients, methods, and results
Four patients with previous myocardial infarction had ventricular arrhythmias. All had previously been in hospital for symptomatic ventricular tachycardia. Three of them had had syncope during ventricular tachycardia and the fourth had been light-headed and weak without actual syncope. Recent myocardial infarction was excluded by an electrocardiogram (ECG) and normal serum enzyme concentrations. Ventricular arrhythmias were recorded and quantified by 24-hour Holter ECG recording. Holter ECG tapes were analysed by digital computer using a method described by Birman et al5 to provide documentation and quantification of ventricular arrhythmias, including frequency, duration, and characteristics. All patients had been treated with quinidine, procainamide, disopyramide, phenytoin, and propranolol until proved to be ineffective, or until adverse effects prevented further use. Drug failure was defined as persistent arrhythmia in the presence of high therapeutic plasma drug concentrations. Previous treatment had been ineffective or had produced intolerable adverse effects. Adverse drug effects had been rash and fever (procainamide), severe diarrhoea (quinidine), striking QT prolongation (quinidine and procainamide), urinary retention (disopyramide), A-V block (propranolol), and severe sinus bradycardia (propranolol). Adverse effects of propranolol alone had occurred only-at doses greater than 480 mg/day. Treatment with mexiletine HC1 was begun with a dose of 200 mg every eight hours. After 48 hours plasma mexiletine concentrations were measured at eight intervals between doses. The mexiletine dose was increased by 300 mg/day every 48 hours until there were adverse effects. The dose was then reduced to the largest dose that did not produce adverse effects and propranolol 240 mg/day was added. Twenty-four hour Holter ECG recordings were made at each level of mexiletine dosing and on combined treatment and were analysed by digital computer. Plasma mexiletine concentrations were measured by nitrogen detection gas chromatography to document adequate drug concentrations.
Number of ventricular premature depolarisations (VPD) per hour and episodes of ventricular tachycardia (VT) per 24 hours in four patients during treatment with mexiletine alone and during treatment with mexiletine plus propranolol All four patients developed adverse effects from mexiletine, without achieving arrhythmia suppression, at doses of 900 or 1200 mg/day (plasma concentration 9-16 pmol/l). After mexiletine was reduced to the highest dose that failed to produce adverse effects and propranolol was added all four patients achieved either greater than 80% suppression of ventricular premature depolarisations or absence of ventricular tachycardia, or both (table) . Plasma mexiletine concentrations did not change significantly during combined treatment with mexiletine and propranolol. Follow-up for 12 to 23 months (mean 17 months) has shown that maintenance treatment has achieved excellent control of ventricular arrhythmia.
Comment
These four cases show that mexiletine and propranolol combined may be effective in severe ventricular arrhythmias when mexiletine alone has either failed or caused adverse effects. Our patients were
